Tay-Sachs, Sandhoff, and LOTS disease is fatal genetic disorder in which harmful quantities of a fatty substance called ganglioside GM2 accumulate due to insufficient activity of an enzyme hexosaminidase. Currently, there is no treatment. Three sub-studies are proposed. Study 1 will focus on the developmental course of the spectrum of infantile Tay-Sachs disease from retrospective data. Study 2 will gather longitudinal prospective data from patients with infantile disease seen at the University of Minnesota to delineate the natural history of Tay-Sachs. Study 3 will be a longitudinal study of LOTS to understand the progression of CNS disease using quantitative methods of neuroimaging and neuropsychological measures. Objectives:
Aim 1 : Develop an index of disease progression in infantile Tay-Sachs disease through: A. First, a retrospective medical chart/record review for clinical data points. Second, participant caretakers of infants with Tay-Sachs disease will be asked to complete the University of Minnesota Natural History Study Questionnaire for Infantile Tay-Sachs Disease (MNQSTD). B. Prospective: We will collect longitudinal neuropsychological and neuroimaging data in patients with infantile Tay Sachs disease to characterize the developmental course and longitudinally examine individual growth trajectories. Predictors will include mutation type, age at diagnosis, biomarkers and surrogate markers such as MRI results.
Aim 2 : To better understand the underlying CNS structure and function abnormalities in LOTS disease and to measure change in function over time through neuroimaging and neuropsychological data. Methods: Infantile: Recruit 5 new patients the 1st year, 10 the 2nd year, and 10 the 3rd year. Each child will be seen yearly for a total of at least 3 or possibly 4 follow-up visits within the 5 year period. LOTS: Participants: Recruit 5 new patients the 1st year and 10 new patients the 2nd year. Each patient will be seen once a year. Both Infantile and LOTS: quantitative neuroimaging, biomarkers, and neuropsychological protocol will be used to collect data as well as relevant medical records.
Currently, there is no treatment for Tay-Sachs disease, and no studies have documented the longitudinal natural history of either the early or late onset disease. The data will provide end-points for future therapies, about treatment and provide objective measurement of treatment outcomes. This information will help objectify disease progression to create a disease stage and severity scale to assist in diagnosis and evaluation of the outcomes of medical treatment of these children. The overall long term goal of this research is to identify brain and behavior abnormalities that can both predict course and be sensitive to change resulting from treatment.
|Eisengart, Julie B; Rudser, Kyle D; Xue, Yong et al. (2018) Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison. Genet Med 20:1423-1429|
|Kazi, Zoheb B; Desai, Ankit K; Troxler, R Bradley et al. (2018) An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease. Genet Med :|
|Schiffmann, Raphael; Swift, Caren; McNeill, Nathan et al. (2018) Low frequency of Fabry disease in patients with common heart disease. Genet Med 20:754-759|
|Shapiro, Elsa; Ahmed, Alia; Whitley, Chester et al. (2018) Observing the advanced disease course in mucopolysaccharidosis, type IIIA; a case series. Mol Genet Metab 123:123-126|
|Ahrens-Nicklas, Rebecca; Schlotawa, Lars; Ballabio, Andrea et al. (2018) Complex care of individuals with multiple sulfatase deficiency: Clinical cases and consensus statement. Mol Genet Metab 123:337-346|
|Ou, Li; Przybilla, Michael J; Whitley, Chester B (2018) Metabolomics profiling reveals profound metabolic impairments in mice and patients with Sandhoff disease. Mol Genet Metab :|
|McIntosh, Paul T; Hobson-Webb, Lisa D; Kazi, Zoheb B et al. (2018) Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy. Mol Genet Metab 123:85-91|
|Nestrasil, Igor; Ahmed, Alia; Utz, Josephine M et al. (2018) Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study. Mol Genet Metab 123:97-104|
|Ou, Li; Przybilla, Michael J; Koniar, Brenda et al. (2018) RTB lectin-mediated delivery of lysosomal ?-l-iduronidase mitigates disease manifestations systemically including the central nervous system. Mol Genet Metab 123:105-111|
|Desai, Ankit K; Walters, Crista K; Cope, Heidi L et al. (2018) Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation. Mol Genet Metab 123:92-96|
Showing the most recent 10 out of 118 publications